Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 15

Transform Your Smile with Gummy Smile Makeover using a Cosmetic Dentist in London

Gummy Smile Makeover

A radiant smile is often regarded as a universal symbol of happiness and confidence. Yet, for some individuals, the aesthetic appeal of their smile may be hindered by what is commonly referred to as a “gummy smile.” With this disorder, which is typified by an overexposure of gum tissue when smiling, one may feel self-conscious and unhappy. Fortunately, this problem has workable answers thanks to developments in cosmetic dentistry. In order to offer readers looking to improve their smiles a thorough guide, we explore the nuances of gummy grin makeovers in this article, using the experience of a cosmetic dentist in London like Marylebone Smile Clinic.

About the Gummy Smile

A gummy smile, or excessive gingival display, is a condition where more gum tissue is visible than is typically considered ideal when a person smiles. This can create a disproportionate look, making the teeth appear shorter or the gums overly prominent. The perception of what constitutes a gummy smile can vary, but it generally involves more than three to four millimeters of gum showing above the upper teeth.

Several factors can contribute to the appearance of a gummy smile. We learn from https://marylebonesmileclinic.co.uk/gummy-smile-makeover-london/ that genetic predisposition plays a significant role, as the shape and size of the jawbone and the way teeth erupt can influence gum exposure. In some cases, an abnormal bite or misalignment of the jaw can cause excessive gum display. Additionally, overactive upper lip muscles can lift the lip too high, revealing more gum tissue. Understanding the underlying causes of a gummy smile is crucial in determining the most appropriate treatment approach.

The Psychological Impact of a Gummy Smile

For many individuals, a gummy smile can lead to self-esteem issues and affect their overall quality of life. The visible excess gum tissue may cause people to feel self-conscious, leading them to avoid smiling or laughing in social situations. This self-imposed restriction can hinder personal interactions and affect one’s confidence and happiness.

Studies have shown that a smile significantly influences first impressions and social perceptions. A genuine, attractive smile is often associated with positive traits such as friendliness, trustworthiness, and approachability. Conversely, a gummy smile might detract from these positive associations, impacting how others perceive an individual. Therefore, addressing a gummy smile is not just about aesthetics; it also involves enhancing psychological well-being and social confidence.

Modern Solutions for Gummy Smile Makeovers

The field of cosmetic dentistry has evolved significantly, offering a range of treatments designed to correct gummy smiles effectively. Depending on the underlying cause of the condition, different procedures can be employed to achieve a balanced and harmonious smile. Here are some of the most common and effective solutions available:

Laser Gum Contouring

Laser gum contouring is a minimally invasive procedure that involves reshaping the gum line to create a more aesthetically pleasing appearance. This technique uses a dental laser to remove excess gum tissue with precision, resulting in less discomfort and a faster recovery time compared to traditional surgical methods.

The procedure typically begins with a thorough examination to determine the extent of gum reshaping required. Local anesthesia is applied to ensure comfort, and the laser is then used to trim and contour the gums. The laser also seals blood vessels as it cuts, minimizing bleeding and promoting quicker healing. The results are immediate, with the new gum line revealing more of the teeth and creating a more balanced smile.

Orthodontic Treatment

In cases where a gummy smile is caused by jaw misalignment or abnormal tooth eruption, orthodontic treatment can be an effective solution. Braces or clear aligners can be used to reposition the teeth and jaws, reducing the appearance of excess gum tissue. This approach not only improves the smile aesthetically but also contributes to better oral health and function.

Orthodontic treatment for gummy smiles may involve moving the teeth into more optimal positions or altering the bite to reduce gum visibility. This process can take several months to years, depending on the complexity of the case. The result is a more aligned smile with improved proportions between the teeth and gums.

Lip Repositioning Surgery

Lip repositioning surgery is an option for individuals whose gummy smile is due to hyperactive upper lip muscles. This procedure involves altering the position of the upper lip to prevent it from lifting too high when smiling. By lowering the upper lip, less gum tissue is exposed, creating a more balanced smile.

During lip repositioning surgery, a small section of tissue from the inside of the upper lip is removed. The remaining tissue is then sutured in a lower position, restricting the movement of the lip when smiling. The surgery is relatively quick, and recovery time is typically short, with patients able to resume normal activities within a few days. The outcome is a more controlled and aesthetically pleasing smile.

Crown Lengthening

The surgical process of crown lengthening exposes more of the tooth’s surface by excising gum tissue and sometimes bone. Those whose teeth seem short because too much gum tissue has covered them are especially benefiting from this therapy. An appealing and proportionate grin is produced by extending the visible part of the teeth.

The procedure is performed under local anesthesia, and a small amount of gum tissue is removed to reveal more of the tooth structure. In some cases, a small portion of the underlying bone may also be removed to achieve the desired result. Crown lengthening lowers the chance of gum disease and makes it easier to keep up proper oral hygiene in addition to improving the smile’s beauty.

Benefits of Gummy Smile Makeovers

Undergoing a gummy smile makeover can have profound benefits beyond aesthetic improvements. Here are some key advantages of addressing this condition:

Enhanced Aesthetic Appeal

One of the most obvious benefits of a gummy smile makeover is the improved appearance of the smile. Reducing the amount of visible gum tissue creates a more balanced and harmonious look, allowing the teeth to be the focal point. This enhancement can lead to a significant boost in self-confidence and willingness to smile openly.

Improved Oral Health

Some treatments for gummy smiles, such crown lengthening and orthodontics, improve dental health. These treatments can help to preserve good oral hygiene by straightening misaligned teeth or lowering too high gum tissue, therefore lowering the risk of gum disease and tooth decay.

Boosted Self-Confidence

Addressing a gummy smile can greatly enhance an individual’s self-esteem and confidence. Feeling more comfortable with one’s appearance encourages more social interaction and a positive outlook on life. This psychological boost can have a ripple effect, improving personal and professional relationships.

Long-Lasting Results

Many gummy smile treatments offer long-lasting results, providing patients with a beautiful smile for years to come. Procedures such as laser gum contouring and crown lengthening can produce permanent changes, while orthodontic treatment offers results that can be maintained with proper care and retention.

Choosing the Right Treatment

Selecting the most appropriate treatment for a gummy smile involves a thorough consultation with a qualified cosmetic dentist. During this consultation, the dentist will assess the specific factors contributing to the gummy smile and discuss the available treatment options. Factors such as the patient’s oral health, aesthetic goals, and budget will be considered in developing a customized treatment plan.

It is important to choose a cosmetic dentist with experience and expertise in treating gummy smiles. A skilled dentist will have a deep understanding of the various techniques and be able to recommend the best approach for achieving the desired results. Patients should feel comfortable discussing their concerns and asking questions to ensure they are well-informed about the procedure.

The Importance of a Healthy Smile

A healthy, attractive smile is more than just a cosmetic asset; it is an important aspect of overall health and well-being. Good oral health contributes to better digestion, clearer speech, and a lower risk of systemic diseases such as heart disease and diabetes. By addressing issues such as a gummy smile, individuals can take a proactive step towards enhancing both their appearance and their health.

In conclusion, a gummy smile makeover offers a valuable opportunity for individuals to transform their smiles and improve their quality of life. With a variety of effective treatments available, those affected by excessive gingival display can achieve a more balanced, aesthetically pleasing smile. Consulting with a London cosmetic dentist can provide the guidance and expertise needed to select the right treatment and enjoy the many benefits of a beautiful, confident smile.

 

Medtronic Hires Dr James Porter, One of the Nation’s Top Surgeons as CMO

Medtronic, a global leader in healthcare technology, today announced that Dr James Porter has joined the company as chief medical officer (CMO) of Robotic Surgical Technologies and Digital Technologies within the Surgical business, which is part of the Medical Surgical Portfolio.

A practicing urologic surgeon who has performed more than 5,000 robotic-assisted procedures, Dr James Porter is a recognized leader among the global surgical community and one of the top five robotic surgery practitioners in the U.S.

He specializes in prostate, kidney cancer, and urinary constructive procedures and his contributions to the field of urologic surgery include the advancement of several groundbreaking surgical techniques employed to treat kidney tumors and testicular cancer in young men.

“I went into medicine because I want to help people and I am absolutely thrilled to now expand the impact on patients to a global scale with Medtronic, a company that I have always admired,” Dr. Porter said. “Tens of millions of patients around the world still lack access to minimally invasive surgical care and I’m excited about our opportunity at Medtronic to make a big impact for humanity. Surgery is fast evolving, due in large part to robotic and digital technologies, and HugoTM and Touch SurgeryTM are leading the way.”

As medical director of robotic surgery with Providence Swedish in Seattle, Wash., part of the larger Providence healthcare system, Dr. Porter helped build one of the highest volume, multispecialty robotic surgery programs in the U.S. He will continue to practice surgery, on a part-time basis, at Providence Swedish.

“Medtronic is privileged to welcome such a renowned physician to our business, and we look forward to Dr. Porter’s contributions as CMO of our robotic and digital divisions as we execute our strategy to scale and continually advance our capabilities to meet customer needs and positively impact patients around the world,” said Rajit Kamal, general manager and vice president of Robotic Surgical Technologies within the Surgical business, which is part of the Medical Surgical Portfolio at Medtronic.

As CMO of robotic and digital technologies within Medtronic’s Surgical business, Dr. Porter will play a key role in driving focus on patients, robotic and digital innovation, the strategic direction of clinical evidence plans, and physician and society engagements.

This week, Dr. Porter will join urologic surgeons from around the world at the European Robotic Urology Society (ERUS) conference, which takes place in Bordeaux, France, from Sept. 11-13.

The conference’s live surgery section will include 12 HugoTM cases, including a partial nephrectomy performed by Dr. Porter. A platinum sponsor of ERUS, Medtronic will also conduct in-booth demos of HugoTM and Touch SurgeryTM Ecosystem, including the recently added Live Stream technology, which securely welcomes remote participants into the live surgery.

U.S. Nursing Care Focused Insights Report 2024-2029

The “U.S. Nursing Care Market – Focused Insights 2024-2029″ report has been added to ResearchAndMarkets.com’s offering.

The U.S. nursing care market was valued at USD 475.15 billion in 2023 and is expected to reach a value of $692.19 billion by 2029, growing at a CAGR of 6.47% from 2023 to 2029.

In the U.S. nursing care market, the major market share is accounted for by the key market players. Due to their high geographical presence, availability of expertise, and well-known brand image of the companies, they do have a better market share in the U.S. The number of mergers and acquisitions is high in the market. In addition, the vendors are producing better innovative plans like luxury accommodations, customized living facilities, and more to attract customers.

The demand for the nursing care market is rising due to multiple factors, including the rising baby boomers, the aging population, increased healthcare expenditures, and an increased preference for independent living.

The occupancy rate for nursing care in the U.S. is rising steadily. Diabetes, increased age, obesity, and other chronic diseases are the key factors that contribute to the rising demand in the U.S. For instance, in 2018, approximately 52 million people aged 65 and above are projected to become about 95 billion by 2060 in the U.S.

By Service type, the skilled nursing segment is showing exponential growth. The growth in this segment is due to the rise in the geriatric population, coupled with increasing chronic diseases and age-associated diseases creating new healthcare opportunities. It is observed that when compared to hospitals, skilled nursing facilities (SNFs) offer high-quality care services at a much lower cost, creating enormous demand among investors.

The public expenditure segment is experiencing significant growth at a CAGR of 6.71%, attributed to rising government support via Medicare services. Long-Term Care Partnership Programs at the state level can safeguard the assets of individuals utilizing Medicaid for long-term care expenses.

The female segment dominated the nursing care market, growing with an absolute growth of 47.81% during the forecast period. Women constitute a majority in assisted living communities due to longer lifespans. The rising aging female population, prevalence of chronic conditions, and proactive healthcare-seeking contribute to women’s preference for assisted living.

The South region of the U.S. accounted for the highest market growth for nursing care. The cost of living is reasonably low compared to other regions, and it is considered a moderately taxed region, making it even more opportunistic for seniors to retire.

MARKET STRUCTURE

  • Market Dynamics
  • Competitive Landscape of Nursing Care Market
  • Key Vendors
  • Other Prominent Vendors

U.S. NURSING CARE MARKET VENDORS LIST

  • Fair Acres
  • RiverSpring Living
  • The Plaza Rehab & Nursing Center
  • NYC Health + Hospitals
  • Laguna Honda
  • Kings Harbor Multicare Center
  • Brookdale Senior Living
  • ProMedica Senior Care
  • Consulate Health Care
  • Ensign Group
  • Genesis Healthcare
  • Life Care Centers of America
  • Humana
  • Enlivant
  • Bayada Home Health Center
  • National Church Residencies
  • Sunrise Senior Living
  • Sonida Senior Living
  • Five Star Senior Living
  • BrightSpring Health Services
  • Fresenius Medical Care
  • Amedisys
  • Eddy Senior Living
  • Embassy Healthcare Services
  • Erickson Senior Living
  • Frontier Senior Living
  • Gardant Management Solutions
  • Bickford Senior Living
  • VNS Health
  • Valeo
  • Pacifica Senior Living
  • Life Care Services
  • MBK Senior Living
  • Hanceville Nursing and Rehab Center
  • Park Avenue Health & Rehabilitation Center
  • Ararat Home of Los Angeles
  • Colorado State Veterans Home
  • A.G. Rhodes

PRODUCT SEGMENTATION & FORECAST

By Service Type

  • Skilled Nursing
  • Home Healthcare
  • Assisted Living
  • Others

By Payment

  • Public Expenditure
  • Private Expenditure

By Gender

  • Female
  • Male

By Geography

  • South
  • Mid-West
  • North-East
  • West

For more information about this report visit here.

Synaptogenix Announces $5.0 Million Financing

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock (“preferred stock”), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the “Registered Offering”) and a concurrent private placement (the “Private Placement” and collectively with the Registered Offering, the “Offering”) of additional shares of Preferred Stock and unregistered common stock purchase warrants. The Offering is expected to close on or about September 12, 2024, subject to the satisfaction of customary closing conditions.

“We are pleased to benefit from the support of our committed long-term investors in this financing,” said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. “This capital enhances our ability to be both strategic and opportunistic as we explore potential acquisitions or fund research on innovative assets, all with the goal of driving growth and maximizing value for our shareholders.”

The shares of Series C preferred stock have an initial conversion price of $4.00 per share and accrue a 5.0% quarterly dividend payable in cash. The warrants have an initial exercise price of $4.00 per common share, are exercisable immediately and are exercisable for a term of five years from the date of issuance.

The securities in the Registered Offering were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-264325), which was declared effective by the Securities and Exchange Commission (the “SEC”) on April 27, 2022. The offering of such securities is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement describing the terms of the Registered Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from GP Nurmenkari, Inc., Attn: Compliance Department, 22 Elizabeth St, Suite 1J, Sono Square, Norwalk, CT 06854, or by telephone at 212-447-5550 or by email at GPNComplaince@gpnurmenkari.com.

The securities in the Private Placement were offered and sold in transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Accordingly, the shares of common stock issuable upon conversion or exercise of the preferred stock and warrants offered and sold in the Private Placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon conversion of the preferred stock and exercise of the warrants issued in connection with the Private Placement.

Getinge Completes the Acquisition of Paragonix Technologies

On August 22, 2024, Getinge announced that it had entered into an agreement to acquire Paragonix Technologies, Inc., a leading U.S. company in organ transport products and services, for a total purchase price estimated at USD 477 million, including upfront and currently estimated earn-outs.

All conditions for the transaction have now been fulfilled, whereupon the transaction was completed today.

Getinge paid approximately USD 253 million in cash upon completion of the acquisition, on a cash and debt free basis. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed USD 224 million in aggregate. The initial payout related to the acquisition has been financed through a bridge loan provided by SEB. The acquisition is expected to have a slightly negative impact on Getinge’s adjusted earnings per share in 2024. Getinge anticipates a positive contribution on adjusted earnings per share starting in 2028.

The deal rationale in brief:

The total market for transplants has been growing rapidly in recent years and is expected to continue to experience double digit growth and exceed USD 10 billion in 2034.

Growth in this market is expected to be driven by volume increase due to demand and the transition from traditional methods (such as ice storage) towards new technologies as the average cost of transplant cases increases. The heart and lung segments have already experienced this trend, and similar development is expected for the abdominal segment.

Paragonix Technologies organ preservation devices and services have seen rapid growth, outgrowing the market significantly in 2023 with 136% growth – seizing substantial market share.

Paragonix Technologies has a strong offering targeting the heart and lung segments; the company’s organ preservation device for hearts has been shown to reduce severe complications by over 50% and reduce in 2-year mortality by 43% compared to traditional heart transport and preservation solutions.

Paragonix Technologies recently launched attractive offerings targeting the abdominal segment and has a strong pipeline of additional products. The company also has a strong portfolio of digital solutions and services.

As close to 100% of Paragonix Technologies’ sales are in the US, there is untapped global potential. Getinge and Paragonix can capture global demand growth together, supported by Getinge’s global commercial infrastructure.

Combining Paragonix Technologies’ leading offering and pipeline with Getinge’s expertise and offering in the acute heart and lung support, digital technologies, and services creates an attractive portfolio of products and services for the global transplant market. The deal also enables the development of new combined offerings for the future – strengthening the leading position further.

Syantra Secures $4.9 Million in Series A-1 Funding; Adds Dr. Rick Mangat to Board of Directors

Syantra, Inc., a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated, announced that it has raised an additional $4.9 million Canadian Dollars in Series A-1 funding.

The funding, which comes from a collective of individuals introduced by CG Wealth Management, along with additional support from existing investors, will empower Syantra to fast-track clinical validation and commercialization of the first test on its patent-pending platform for early detection of breast cancer. Syantra has an ISO 13485:2016-accredited quality management system and has received CLIA/COLA and CPSA lab accreditations for use of the test in the United States and Canada, respectively. Other regulatory approvals include CE-IVD and UKCA Marking for kit distribution outside North America.

Syantra also announced the addition of Dr. Rick Mangat to its Board of Directors. Dr. Mangat brings over 20 years of experience as a medical device executive. Dr. Mangat co-founded NOVADAQ Technologies Inc. in 2000 and served as the company CEO until the company was acquired in September 2017.

These announcements follow recent related news wherein Cornell University and the University of Calgary (UC) received partnering awards from the U.S. Department of Defense (DoD) for a total of more than $2.4 million US Dollars to fund a three-year, 2,000 participant clinical study to expand work with Syantra’s early breast cancer detection blood test at six sites in the US and United Kingdom.

UC’s Kristina Rinker, PhD, a Syantra co-founder, is a partner principal investigator on the multinational project. The clinical study will evaluate the Syantra DX™ Breast Cancer test in new and diverse populations.

Rob Lozuk, CEO Syantra:

“We’re on the cusp of something transformative here, in both fulfilling the mission and furthering the growth of Syantra. On the heels of the DoD project, this influx of support will empower Syantra to focus on the science that drives us forward, enabling the team to execute ongoing clinical studies and other efforts prior to ramping up commercialization in 2025.”

He added, “The in-house R&D team, along with our select group of partners and investors, comprises forward-thinking scientific leaders who recognize that current detection methods can be ‘too little, too late,’ because, in the case of breast cancer, by the time a mammogram detected abnormality is biopsied, the cancer may have already established a firm foothold.”

Far too often, breast cancer is being detected at later stages when treatment may not be as effective. There are a few reasons for this, including that mammography-based screening isn’t available to all age groups, and women who do qualify don’t always participate in testing. Secondly, dense breast tissue — which more than 50% of women have — reduces the sensitivity of mammograms, which can impact the ability to detect early stage cancer. “The Syantra DX™ Breast Cancer test demonstrates both the singular science and vision of Syantra”, according to Lozuk. “With an ever-increasing number of women being diagnosed at younger ages, we wanted to create a test that offered a different but complementary approach to identifying women who need a diagnostic image. With the Syantra DX™ Breast Cancer test, we believe we will deliver exactly that.”

The Syantra DX™ Breast Cancer test is the first test developed on Syantra’s biotechnology platform. It measures a panel of gene expression biomarkers from whole blood and produces a test result with machine learning informed software, with 92% clinical accuracy in blinded clinical studies.1

“With the DoD project and this new round of funding, we’re excited to build on the success of the Syantra DX™ Breast Cancer test, and help revolutionize early cancer detection across the board,” said Lozuk. “And with the addition of Dr. Mangat to the board, we’re not only adding scientific leadership; we’re adding commercialization leadership and experience as he played a central role in building successful companies in our space, Novadaq, which was one the largest medical device company sales in Canadian history.”

1: The Syantra DX™ Breast Cancer test has been evaluated in clinical studies for women between the ages of 25 and 80, with results showing an inferred accuracy of 92%. Bundred, N. et al., Breast Cancer Whole Blood Screening: Analytical and Clinical Performance from Early Analysis of the International Identify Breast Cancer (IDBC) Study,: European Journal of Cancer, Volume 175, Supplement 1S, 10.1016/S0959-8049(22)01365-X.

Luba Greenwood Is Appointed Chair of the Board of Directors of Closed Loop Medicine

Closed Loop Medicine Ltd., a leading TechBio company leveraging AI, machine learning, and personalized dosing to enhance drug development, today announced the appointment of Luba Greenwood as Chair of its Board of Directors.

Luba Greenwood is a distinguished executive and investor with over 20 years’ experience in healthcare and tech. She has led over $10 billion USD in deals and investment over multiple therapeutic areas, leading success and scaling companies across the life sciences, medical devices, diagnostics, and tech sectors, including co-founding biotech and digital companies in the immunotherapy, women’s health, AI/ML and microbiome space. Leveraging broad corporate experience alongside legal and technical expertise, Luba’s appointment to Closed Loop Medicine’s Board will be instrumental in supporting development of the Company’s partnering and growth outside of the UK.

Luba Greenwood is currently the Managing Partner of Binney Street Capital (BSC), a venture fund she founded at the Dana-Farber Cancer Institute and has previously served as CEO and Chair of Kojin Therapeutics, a company developing small-molecule therapeutics for a wide range of diseases. She has previously held leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and M&A at Roche, where she established the East Coast Innovation Hub. Luba is a former lawyer with deep understanding of corporate governance and regulatory, policy, and intellectual property across the pharmaceutical, biotechnology, and technology industries.

Luba has served on the Boards and as an advisor to numerous private and publicly-traded companies, including Abcam, spearheading the sale to Danaher in 2023, and the non-profit Massachusetts Biotechnology Council (MassBio).

The news follows in a series of high-profile appointments to Closed Loop Medicine’s Board, including digital healthcare leader, Paul Johnson, founder and former CEO of Lemonaid Health, as Non-Executive Director in May 2024 (1), and David Van Sickle, former CEO and Co-Founder of Propeller Health, a digital health and medtech company that launched one of the first integrated software and device combination interventions transforming respiratory disease (2). Luba’s appointment as Chair demonstrates another integral stage in the Company’s strategy as it prepares for breakthrough milestones in the progression and commercialization of its product pipeline.

Luba Greenwood, Chair of the Board of Closed Loop Medicine, commented: “By catalyzing the development of more precise therapeutics across vast disease areas, Closed Loop’s platform has the potential to not only improve drug safety and efficacy, but transform the way healthcare is delivered.” She added: “The work I do—and have been doing—has been driven by my dedication to bringing innovative products to market and ultimately to patients. I’m excited to be a part of the Company’s pioneering journey for better medicines, alongside a very impressive Board of Directors, to bring precision medicines to all patients in need.”

Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, said: “On behalf of the entire team at Closed Loop, I am delighted to welcome Luba as Chair of our Board. Her impressive background and expertise in healthcare and tech, particularly as it pertains to the US market, will be instrumental in bolstering the Company’s strategic growth. With her strong track-record of building world-class teams and companies, we are well-positioned for the commercialization of our products and the expansion of our partnerships.”

AI Can Detect Lung Nodules that Could Lead to Lung Cancer Nearly 3 Years Before Symptoms & Actual Diagnosis | Study finds

AI Can Detect Lung Nodules: A new study has been unveiled at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancerin San Diego, CA citing promising initial results using AI-powered chest X-ray interpretation to detect pulmonary nodules which could develop into early-stage lung cancers long before symptoms appear. The retrospective study demonstrated via interim results, an average diagnostic delay of nearly three years from the first abnormal chest X-ray.

The study conducted at the Phrapokklao Hospital’s Cancer Centre of Excellence in Bangkok, Thailand was led by Dr Passakorn Wanchaijiraboon, Medical Oncologist and Deputy Director using the Qure.ai chest X-ray AI solution qXR.

Dr. Passakorn Wanchaijiraboon, while unveiling the poster, said;

“This abstract study, presented at the World Conference on Lung Cancer, provides a snapshot of the significant potential that AI-assisted chest X-ray analysis holds for transforming early cancer detection and reducing the rate of missed lung cancer diagnoses. In most Thai government hospitals, chest X-rays are interpreted by non-radiologists. However, in community hospitals, there are often no radiologists available to read chest X-rays at all. By overlaying specialist AI to read all cases, we can support clinicians in detecting incidental high-risk nodules that may lead to lung cancer. This approach can streamline decision-making and potentially improve patient survival through the earlier diagnosis of cancer. The implementation of CXR AI is particularly beneficial in the context of community hospitals, where it can significantly enhance diagnostic capabilities in the absence of on-site radiologists.” 

The Phrapokklao Cancer Centre study retrospectively reviewed and evaluated the chest X-ray image database of newly diagnosed lung cancer patients over an annual period using qXR. Missed lung cancer was defined as missed in the original report six months prior to a definitive lung cancer diagnosis. 18% of patient cases were found to have a missed lung cancer diagnosis over an average period of nearly three years (32.3 months), with a maximum duration of over eight years (96 months) and minimum eight months. Half the patient cases had chest X-rays taken for non-respiratory symptoms as part of a health check-up, categorising them as ‘incidentally detected’.

Bhargava Reddy, Chief Business Officer, Oncology at Qure.ai

“This is an exciting evidence example that underscores the transformative potential of AI in the fight against lung cancer. Overlaying AI on chest X-rays casts the net wider by proactively triaging patients for the risk of lung cancer. It goes beyond people with symptoms or qualifying for screening initiatives based on age or smoking history, to currently invisible and unprofiled patient populations thus detecting lung cancers earlier.”

Lung Cancer has one of the poorest survival outcomes of all cancers, with over two-thirds of patients diagnosed at an advanced stage, when curative treatment is no longer feasible1. Missed lung cancer is a source of concern for clinicians and an important medicolegal challenge2. Missed nodules resulting from lung cancer are the third most common reason for malpractice claims 3.

IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) is being held September 7 to 10 in San Diego, California. The Phrapokklao Cancer Centre study poster abstract presented can be viewed here: https://www.qure.ai/evidence/The-potential-of-chest-X-ray-Al-in-detecting-missed-lung-cancer-diagnosis-in-a-community-based-cancer-center-in-thailand

Ai Can Detect Lung Nodules News
A case of maximum missed lung cancer nodules, diagnosis duration of 97 months
1st image: Prior Chest X ray; 2nd Image: AI result; 3rd Image: Chest X ray at diagnosis
Ct Image At Diagnosis
CT image at diagnosis
Ai Can Detect Lung Nodules
Chest X ray of patient with nodule detected by AI/qXR 23 months prior to the diagnosis of lung cancer. The X-ray was obtained as a part of health check-up.

References

1,2 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338577/

3 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431813/

 

Correlation Between Mental Disorders & Addiction: What You Need to Know

Correlation Between Mental Disorders & Addiction: What You Need to Know

Did you know that there is a correlation between mental disorders and addiction? In fact, about 50% of people who struggle with addiction also have a mental disorder. This can make treatment for both issues more complicated. It’s important to understand the correlation between mental disorders and addiction in order to get help for yourself or a loved one. In this blog post, we will discuss the link between mental disorders & addiction, as well as what you need to do if you are struggling with either issue.

1. The Link Between Mental Disorders and Addiction:

People who suffer from mental disorders are more likely to turn to substances as a way to cope with their symptoms. This might be due to the fact that they have lower levels of dopamine, which is a neurotransmitter associated with pleasure. By using drugs or alcohol, the person can achieve some degree of relief from the symptoms of their disorder. This is why it is important to have a dual diagnosis and treat both issues at the same time. For example, someone who has both depression and addiction should receive treatment for both disorders at the same time.

2. Why This Correlation Exists:

It is believed that genetic factors may play a role in this correlation. People with certain genetic predispositions are more likely to turn to drugs or alcohol as a way of self-medicating. Additionally, many people with mental health issues struggle with social interaction and lack of support, which can lead them to seek solace in substances. Having an understanding of why the person is turning to substances can help create a better plan for treating both issues simultaneously.

3. What To Do If You Have Mental Disorders & Addiction:

If you or someone you know is struggling with both mental health issues and an addiction, it is important to seek help as soon as possible. Dual diagnosis treatment is the best way to handle this situation because a professional can help you create a plan that treats both issues at the same time. This will increase the likelihood of successful treatment and long-term sobriety. Additionally, you should consider joining support groups so that you can learn from other people who are going through similar experiences.

4. The Importance of Seeking Help:

It is essential to seek help if you are struggling with both mental health issues and addiction. Seeking professional help can provide the support and guidance you need in order to address both issues at the same time. Without proper treatment, it is unlikely that either issue will be managed successfully in the long run. Additionally, having a support system of family and friends can make a huge difference when dealing with these types of issues.

5. What to expect during treatment:

Treatment for both addiction and mental health issues can be a long process. Treatment may include individual counseling, group therapy, medication management, lifestyle changes, and more. Additionally, it is important to find a treatment program that offers family support as well. This can help ensure that everyone involved in the recovery process has the tools they need to succeed. For example, family members can provide support and understanding to the person recovering, while professionals can offer more in-depth guidance.

6. The Benefits of Dual Diagnosis Treatment:

Dual-diagnosis treatment can provide major benefits to those who suffer from both mental health issues and addiction. This type of treatment is tailored to the individual’s needs, so it will address both issues simultaneously. Additionally, this form of treatment helps prevent relapse by taking a holistic approach to recovery. Finally, dual diagnosis treatment provides the necessary support system for long-term sobriety and improved mental health.

7. What are the warning signs:

The warning signs of mental disorders and addiction can vary depending on the individual. But some common signs include changes in behavior, withdrawal from social activities, frequent mood swings, feelings of depression or anxiety, excessive drug or alcohol consumption, and more. It is important to be aware of these signs so that you can intervene as soon as possible if needed.

By understanding the correlation between mental disorders and addiction, it is possible to create a plan for successful treatment and long-term sobriety. By addressing both issues at the same time with dual diagnosis treatment, individuals can learn how to cope with their symptoms in a healthy way. Additionally, having a strong support system of family and friends is an essential part of recovery. If you are struggling with both mental health issues and addiction, it is important to seek help as soon as possible. Understanding the warning signs of these conditions can also help you recognize when someone needs support. With the right guidance and treatment plan, it is possible to make a full recovery.

 

Withings Sleep Rx Receives FDA Clearance for the First Contactless Device to Aid in the Diagnosis of Sleep Apnea

Withings, a global leader in connected health, announces that its Sleep Rx Mat has received clearance from the U.S. Food and Drug Administration. Sleep Apnea is not only severely underdiagnosed worldwide – but also diagnosed using solutions that have shown limitations, in both access and accuracy. By addressing these challenges, the release of Sleep Rx in the US will mark a new era in sleep apnea diagnosis, paving the way to better health outcomes for millions of adults in the US.

Addressing The Growing and Underdiagnosed Sleep Apnea Crisis

Obstructive Sleep Apnea (OSA) affects approximately 30 million adults in the U.S., with a staggering 80% of cases going undiagnosed1. Traditional diagnostic methods, such as Polysomnography (PSG), are limited to diagnosing only the most severe sleep disorders due to their low availability and high cost. PSG is also bulky and intrusive2, requiring an overnight stay in a sleep lab, which many patients find inconvenient. Moreover, a single-night assessment may not accurately represent the severity of OSA, as it can fluctuate from night to night, leading to potential error rates of up to 50%3.

The underdiagnosis of OSA is highly problematic because untreated OSA significantly increases cardiometabolic risks, including diabetes mellitus4, resistant hypertension5, atrial fibrillation6, stroke, and myocardial infarction7.

“We’re thrilled to bring Sleep Rx to the U.S. market,” said Antoine Robiliard, VP of Withings Health Solutions. “Enabling earlier and more precise diagnosis, Sleep Rx creates a new sleep apnea diagnosis and management paradigm. We know that a one-night assessment is not sufficient. By enabling more efficient and lower-cost home-based OSA diagnosis, Sleep Rx could not only reduce the staggering $150 billion annual economic burden of undiagnosed sleep apnea but also significantly improve long-term health outcomes.”

Advanced Sleep Insights at Home

Sleep Rx is an advanced sleep device clinically validated for use in home screening of adults with suspected sleep breathing disorders as an aid for diagnosis of OSA, sleep analysis, and heart rate estimation. The sleek, unobtrusive mat requires a one-time set up, fits under any mattress, eliminating the need for masks or cumbersome equipment. Once set up, it provides detailed analysis of sleep, breathing, and cardiovascular activity throughout the night.

Available in the U.S. by prescription as part of clinical sleep management or remote patient monitoring programs, Sleep Rx can be acquired by healthcare professionals through Withings Health Solutions. It represents a major advancement in the early diagnosis of sleep apnea, using a pneumatic sensor to measure respiratory rate, body movement, and continuous heart rate, along with tracking sleep cycles, duration, and interruptions. Sound and motion sensors detect snoring and breathing disturbances, key indicators of sleep apnea. Each morning, Sleep Rx provides a comprehensive sleep quality score, giving patients an easy-to-understand assessment of their rest.

Revolutionizing Sleep Apnea Patient Journey

Global studies have shown Sleep Rx’s potential to impact every step of the patient’s journey from diagnosis3 to treatment efficacy8. By offering a scalable, accurate, and comprehensive diagnostic solution, Sleep Rx is set to profoundly improve the lives of millions of Americans. As a non-intrusive solution, Sleep Rx can provide longitudinal data. This is a game changer, given that a study of over 11 million nights by Flinders Health and Medical Research Institute using Withings Sleep tracking mats revealed significant variability in the apnea-hypopnea index (AHI) from night to night, highlighting the need for longer-term follow-up—something Sleep Rx now makes possible3.

Availability
Sleep Rx is now available in the U.S. by prescription. For more information about Sleep Rx and Withings’ ongoing commitment to digital health innovation, visit www.withingshealthsolutions.com/connected-devices/sleep-rx.

Learn about Linkhouse today!

1...141516...923Page 15 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330